Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed dosing in ASSURE, a Phase 2b clinical ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") today announced that its Board of Directors has approved ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with Coronary Artery Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial ... weiter zur Pressemitteilung von Resverlogix Corp.
Munich And Calgary, Alberta (ots/PRNewswire) - -- Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period -- -- Results from ASSURE Study Expected H1 2013, Using IVUS to Measure Regression of Atherosclerotic Plaque -- ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Alberta (ots/PRNewswire) - This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") today announces the "Mechanism of Action" (MoA) by which ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Alberta (ots/PRNewswire) - Dr. Stephen J. Nicholls joins as guest speaker TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") is pleased to announce for the first time the "Mechanism of Action" (MoA) by which ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") announced today that two abstracts on the analysis of the ASSERT trial were presented at the European Society of Cardiology (ESC) Congress 2011 in Paris, France. The abstracts were ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Alberta (ots/PRNewswire) - Resverlogix announced today that its lead drug RVX-208, a first in class ApoA-I production drug, illustrated positive effects on an important cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid ... weiter zur Pressemitteilung von Resverlogix Corp.
Chicago, November 17 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") announces its top line results of the ASSERT Phase 2 clinical trial which will be highlighted at the prestigious American Heart Association Scientific Sessions 2010 Late ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that Mr. Kenneth Zuerblis has been appointed to the Company's Board of Directors. Recently Mr. Zuerblis served as the Chief Financial Officer and Senior ... weiter zur Pressemitteilung von Resverlogix Corp.
Hamburg and Calgary, Canada, June 22, 2010 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that the Board of Directors has elected Arthur J. Higgins, CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee, to ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - Powerful Effects Seen in all Subjects Including Those With Low HDL - Representing a Majority of Myocardial Infarct Patients TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada, November 10 (ots/PRNewswire) - - First in Class Drug Illustrates Early Signal of Transport of Key Amyloid Marker From Brain - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that treatment with ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - Provides Shareholders With an Update on Strategic Review Activities On behalf of Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) the Board of Directors, due to the recent advancement of various ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - Multiple Presentations Included Resverlogix Data - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Dr. Norman Wong presented key clinical data ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - RVX-208 is the Only Apo-Al/HDL Drug to be Highlighted Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is featured prominently in an article titled ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp's ("Resverlogix" or the "Company") (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been selected as one of the top 10 most promising cardiovascular disease (CVD) drugs available for ... weiter zur Pressemitteilung von Resverlogix Corp.
San Diego, California and Calgary, Canada (ots/PRNewswire) - - Findings Demonstrate Clear Trends of Proof of Principle of Reverse Cholesterol Transport in Human Volunteers SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ -- ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - Phase 1a Study Objectives Were Met - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - Resverlogix Sees Early Success and Expedites Phase 2 Plans TSX Exchange Symbol: RVX Resverlogix is pleased to announce preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty ... weiter zur Pressemitteilung von Resverlogix Corp.
Calgary, Canada (ots/PRNewswire) - - New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to ... weiter zur Pressemitteilung von Resverlogix Corp.
| Presseportal: 3,86 Mio Visits im April Quelle: 
FEEDS
